Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 After 3 Weeks of Treatment in Patients With Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN)

NCT00976534 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00976534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00976534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 After 3 Weeks of Treatment in Patients With Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2009
Completion date
February 28, 2010
Enrollment
90 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

neuropathic pain, pain